

Fig. 4

Schematic view of male hypothalamic MPOA at PND 2. The enclosed area was microdissected from sections of methacarn-fixed paraffin-embedded brain slices for gene expression analysis. Note the intensely stained SDN region. Abbreviations: OC: optic chiasm; 3V: 3rd ventricle; MPOA: medial preoptic area; SDN-POA: sexually dimorphic nucleus of preoptic area.





Fig. 5
Schematic view of male hypothalamic MPOA at PND 10. The enclosed area was microdissected from sections of methacarn-fixed paraffin-embedded brain slices for gene expression analysis. Note the intensely stained SDN region. Abbreviations: AC: anterior commissure; 3V: 3rd ventricle; MPOA: medial preoptic area; SDN: sexually dimorphic nucleus.




*p<0.05, vs. corresponding control

**p<0.01, vs. corresponding control

Fig. 6

Serum sex steroid levels in offspring exposed gestationally and lactationally to DBP, DINP, or DEHA.



*: **: Significantly different from the corresponding controls (* $p<0.05$, ** $p<0.01$).
#: ##: Significantly different from male values (# $p<0.05$, ## $p<0.01$).

Fig. 7
Confirmation of microarray data by real-time RT-PCR in the EE study.




Fig. 8
Confirmation of microarray data by real-time RT-PCR in the DEHP study.




Fig. 9

Gene expression data for the MPOA at PND 10 of pups exposed maternally to EE. Data are ratios to male control values, expressed as mean \pm SD, and normalized for the input amount of total RNA, or expression of GAPDH or HPRT. #, ##: Significant differences between males and females ($*p < 0.05$, $**p < 0.01$ by Student's *t*-test). *, **: Significant differences from the controls of the corresponding sex ($*p < 0.05$, $**p < 0.01$ by Student's *t*-test).




Fig. 10

Gene expression data for the MPOA at PND 10 of male pups exposed maternally to MXC. Data are ratios to control values, expressed as mean \pm SD, and normalized for the input amount of total RNA, or GAPDH- or HPRT-expression. *: Significantly different from the controls ($*p < 0.05$ by Dunnett's test).




Fig. 11

Gene expression data for the MPOA at PND 10 of female pups exposed maternally to MXC. Data are ratios to control values, expressed as mean \pm SD, and normalized for the input amount of total RNA, or GAPDH- or HPRT-expression. *: Significantly different from the controls ($*p < 0.05$ by Dunnett's test).




Fig. 12

Gene expression data for the MPOA at PND 10 of male pups exposed maternally to DNP or GEN. Data are ratios to control values, expressed as mean \pm SD, and normalized for the input amount of total RNA, or GAPDH- or HPRT-expression.




Fig. 13

Gene expression data for the MPOA at PND 10 of female pups exposed maternally to DINP or GEN. Data are ratios to control values, expressed as mean \pm SD and normalized for the input amount of total RNA, or GAPDH- or HPRT-expression. *: Significantly different from the controls ($*p < 0.05$ by Dunnett's test).

Table 1

Summary of the previously assessed endocrine effects of EACs in offspring after perinatal exposure.

Chemical	Sex	Dose (ppm in diet)	Results
EE ^{a,c}	M	0.5	Reduced neonatal body weights and body weight gain during PNDs 2-10 Delayed onset of puberty Decrease of SDN-POA volume
	F	0.5	Reduced neonatal body weights and body weight gain during PNDs 2-10 Early onset of puberty Irregularity in estrous cyclicity Increased relative weights of adrenals and pituitaries at PNW 11 Histopathological alterations in the endocrine organs at PNW 11 - Increase of follicles/decrease of corpora lutea in the ovaries - Hypertrophy of the endometrial epithelium - Diffuse hyperplasia of the anterior pituitaries - Lobular hyperplasia in the mammary glands Population changes in the pituitary hormone-immunoreactive cells - Increase of the PRL-immunoreactive cell ratio at PNW 3
MXC ^{b,d}	M	24, 240	No alterations in the endocrine/reproductive system
		1200	Reduced body weight gain during PNDs 2-10 Reduced absolute and relative weights of the testes at PNW 3 Delayed onset of puberty Population changes in the pituitary hormone-immunoreactive cells - Decrease of LH-, FSH-, and PRL-immunoreactive cell ratios at PNW 3
F	24		No alterations in the endocrine/reproductive system
	240		Pituitary hormone-immunoreactive cell population - Increase of PRL at PNW 11
	1200		Reduced body weight gain during PNDs 2-10 Early onset of puberty Irregular estrous cyclicity Decreased absolute and relative weights of the ovaries at PNW 11 Histopathological alterations in the endocrine organs at PNW 11 - Increase of follicles/ decrease of corpora lutea in the ovaries - Hypertrophy of the endometrial epithelium - Diffuse hyperplasia of the anterior pituitaries - Vaginal mucosal hyperplasia - Lobular hyperplasia of the mammary glands Population changes in the pituitary hormone-immunoreactive cells - Decrease of LH-immunoreactive cell ratio at PNW 3 - Increase of FSH- and PRL-immunoreactive cell ratios at PNW 11
DINP ^{b,d}	M/F	400, 4000	No alterations in the endocrine/reproductive system
	M	20,000	Reduced body weight gain during PNDs 2-10 and PNDs 21-42 Reduced absolute and relative weights of the testes at PNW 3 Histopathological alterations in the gonadal organs at PNW 11 - Degeneration of meiotic spermatocytes at stage XIV in the testes - Vacuolar degeneration of Sertoli cells in the testes
F	20,000		Reduced body weight gain during PNDs 2-10 Histopathological alterations in the gonadal organs at PNW 11 - Decrease of corpora lutea in the ovaries
GEN ^{b,d}	M	20, 200, 1000	Reduced body weights of males at PNW 11
	F	20, 200, 1000	No alterations in the endocrine/reproductive system

Data are summarized from ^a Masutomi et al. (2004a), ^b Masutomi et al. (2004b), ^c Shibutani et al. (2005), and ^d Masutomi et al. (2003), respectively.

Abbreviations: EE, ethinylestradiol; MXC, methoxychlor; DINP, diisonyl phthalate; GEN, genistein; M, males; F, females; PND, postnatal day; SDN-POA, sexually dimorphic nucleus of the preoptic area; PNW, postnatal week; PRL, prolactin, LH, luteinizing hormone; FSH, follicle-stimulating hormone.

Table 2Sequences of primers and probes used for real-time RT-PCR^a

Gene	Accession No.		Sequence	Product size
ER α	Y00102	sense	5'-GGGCTTCCCCAACACCAT-3'	65 bp
		antisense	5'-CGTTTCAGGGATTGCGCAGAA-3'	
		probe ^b	5'-TGAGAACTCCCAAGGCTCCCCACAA-3'	
ER β	U57439	sense	5'-TGCTGGATGGAGGTGCTAATG-3'	82 bp
		antisense	5'-CGAGGTCGGGAGCGAAA-3'	
PR	NM_022847	sense	5'-GGGCACTGGCTGTGGAATT-3'	77 bp
		antisense	5'-CATGCCGCCAGGATCT-3'	
SRC-1	XM_233944	sense	5'-CCAGGCCAGCAGAAGAG-3'	65 bp
		antisense	5'-CACATTCTTAAAAGTGGTTATTCACT-3'	
		probe ^c	5'-CTCCTTCAGCAGCTAC-3'	
SRC-2	NM_031822	sense	5'-CCGCCAGCCGCTAATG-3'	64 bp
		antisense	5'-GCCAGGCCTCAAAGTCAAGTT-3'	
		probe ^b	5'-CCAGATCAGCGGCCTTCCAATG-3'	
GnRH	M31670	sense	5'-CCCCAGAACCTCGAATGCA-3'	70 bp
		antisense	5'-GTTCCAGAGCTCTGCAGAT-3'	
		probe ^b	5'-CGAGGTCGGGAGCGAAA-3'	
CALB	M27839	sense	5'-AGAATTCTGCTGCTCTTCG-3'	77 bp
		antisense	5'-GTCATACTTCTCCAAGTCTTCATGAA-3'	
		probe ^b	5'-TGCCAGCAACTGAAGTCCTGCGA-3'	
HPRT	X62085	sense	5'-GCCGACCGGTTCTGTCAT-3'	71 bp
		antisense	5'-GGTCATAACCTGGTTCATCATCAC-3'	
		probe ^c	5'-CAGTCCCAGCGTCGTG-3'	

^aFor GAPDH, commercially available TaqMan[®] Rodent GAPDH Control Reagents (Applied Biosystems) were used (Sequence information not available).

^b TaqMan[®] probe.

^c TaqMan[®] MGB probe.

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; SRC, steroid receptor coactivator; GnRH, gonadotrophin releasing hormone; CALB, calbindin-D; HPRT, hypoxanthine-guanine phosphoribosyl transferase.

Table 3. Effects on dams and offspring until prepubertal necropsy of exposure to diisononyl phthalate (DINP) during late gestation and lactation.

	DINP in diet (ppm)			
	0	400	4000	20,000
No. of dams examined	8	10	8	10
Maternal parameter				
BW change (g/day)				
GD15-GD20	13.2 ± 3.4 ^a	13.8 ± 1.7	14.7 ± 2.1	6.1 ± 1.6**
PND2-PND10	4.7 ± 1.9	4.5 ± 2.2	4.8 ± 1.4	-0.9 ± 2.0**
PND10-PND21	-1.6 ± 1.2	-1.2 ± 1.3	-0.5 ± 0.8	-2.4 ± 1.5
Food intake (g/day)				
GD15-GD20	27.0 ± 2.7	27.4 ± 2.8	26.4 ± 2.9	15.4 ± 2.9**
PND2-PND10	41.6 ± 5.7	42.1 ± 3.5	42.0 ± 3.6	29.2 ± 4.5**
PND10-PND21	53.5 ± 12.9	55.8 ± 7.0	53.1 ± 11.6	38.0 ± 5.7**
DINP intake (mg/kg/day)				
GD15-GD20	0	28.4 ± 2.5	269.9 ± 18.4	825.8 ± 146.4
PND2-PND10	0	51.0 ± 6.4	506.4 ± 46.7	2142.1 ± 241.9
PND10-PND21	0	62.8 ± 10.8	593.4 ± 140.3	2823.9 ± 296.3
Duration of pregnancy (days)	21.4 ± 0.5	21.8 ± 0.4	21.6 ± 0.5	21.4 ± 0.5
Offspring parameter				
No. of live offspring	12.3 ± 3.5	13.3 ± 3.3	14.3 ± 1.8	13.5 ± 1.4
Male ratio (%)	47.5 ± 16.9	45.2 ± 14.1	50.0 ± 12.1	49.5 ± 8.9
Body weight at PND2 (g)				
Males	7.5 ± 1.0	7.4 ± 0.8	7.1 ± 0.6	5.8 ± 0.8**
Females	7.0 ± 0.9	7.0 ± 0.9	6.7 ± 0.6	5.6 ± 0.8**
AGD at PND2 (mm)				
Males	4.0 ± 0.2	4.2 ± 0.2	4.1 ± 0.2	3.8 ± 0.3
Females	2.1 ± 0.1	2.2 ± 0.2*	2.2 ± 0.1*	2.1 ± 0.1
Nipples/areolae in males at PND 14				
No. of identified animals (%)	0%	19.4%*	34.6%**	30.8%**
Relative organ weights at PNW 3				
No. of animals examined	10	10	10	10
Males				
BW (g)	62.0 ± 4.5 ^a	55.4 ± 5.0**	54.0 ± 4.4**	26.0 ± 3.8**
Liver (g/100g BW)	3.85 ± 0.12	3.68 ± 0.27	3.97 ± 0.31	3.85 ± 0.34
Kidneys (g/100g BW)	1.09 ± 0.06	1.10 ± 0.08	1.24 ± 0.07**	1.29 ± 0.12**
Brain (g/100g BW)	2.48 ± 0.13	2.73 ± 0.21	2.84 ± 0.23*	5.18 ± 0.56**
Adrenals (mg/100g BW)	27.9 ± 4.3	23.4 ± 5.2	25.6 ± 7.0	19.4 ± 11.8
Testes (g/100g BW)	0.38 ± 0.08	0.42 ± 0.03	0.44 ± 0.03	0.47 ± 0.04*
Epididymides (g/100g BW)	0.06 ± 0.02	0.07 ± 0.01	0.07 ± 0.01	0.09 ± 0.02**
Females				
BW (g)	60.3 ± 5.2	54.2 ± 4.5**	51.6 ± 2.2**	25.1 ± 3.1**
Liver (g/100g BW)	4.07 ± 0.22	3.83 ± 0.21	4.04 ± 0.32	4.13 ± 0.24
Kidneys (g/100g BW)	1.19 ± 0.07	1.17 ± 0.07	1.26 ± 0.09	1.30 ± 0.06**
Brain (g/100g BW)	2.50 ± 0.17	2.73 ± 0.17	2.85 ± 0.12*	5.24 ± 0.52**
Adrenals (mg/100g BW)	24.9 ± 5.9	25.5 ± 4.6	25.7 ± 7.5	23.4 ± 13.6
Ovaries (mg/100g BW)	27.8 ± 11.8	29.6 ± 7.5	26.6 ± 3.5	23.7 ± 10.6
Uterus (g/100g BW)	0.06 ± 0.01	0.07 ± 0.01*	0.08 ± 0.01*	0.11 ± 0.02**

* Mean ± SD.

Abbreviations: GD, gestational day; PND, postnatal day; PNW. Postnatal weeks; BW, body weight; AGD, anogenital distance.

* , **: Significantly different from the controls (* p<0.05, ** p <0.01).

Table 4. Onset of puberty and estrous cyclicity in the offspring exposed to diisononyl phthalate (DINP) during the late gestation and lactation periods.

	DINP in diet (ppm)	0	400	4000	20,000
Onset of puberty					
Male					
Age by day		41.8 ± 2.1 ^a	41.9 ± 1.7	40.8 ± 1.4	45.9 ± 2.8 ^{**}
BW at onset (g)		204.0 ± 19.1	198.9 ± 19.5	187.7 ± 11.9 ^{**}	165.2 ± 14.2 ^{**}
Female					
Age by day		34.8 ± 1.8	34.4 ± 1.7	34.1 ± 1.5	38.3 ± 3.1 ^{**}
BW at onset (g)		125.8 ± 11.4	120.3 ± 14.6	117.7 ± 15.0	98.9 ± 11.6 ^{**}
Estrous cyclicity					
PNW 8-11 (ED)		10 (0)	10 (1)	10 (2)	10 (1)
PNW 17-20 (ED)		10 (2)	10 (2)	10 (1)	10 (1)

^a Mean ± SD.

Abbreviations: BW, body weight; ED, extended diestrus.

* , **: Significantly different from the controls (* $p < 0.05$, ** $p < 0.01$).

Table 5. Organ weights at necropsy in PNWs 11 and 20 for offspring exposed to diisononyl phthalate (DINP) during the late gestation and lactation periods.

	DINP in diet (ppm)			
	0	400	4000	20,000
PNW 11				
No. of animals examined	10	10	10	10
Males				
BW (g)	437.2 ± 32.9 ^a	422.5 ± 30.6	401.4 ± 29.5*	327.3 ± 29.3**
Liver (g/100g BW)	3.39 ± 0.21	3.35 ± 0.17	3.25 ± 0.27	3.24 ± 0.15
Kidneys (g/100g BW)	0.65 ± 0.04	0.65 ± 0.05	0.65 ± 0.04	0.66 ± 0.06
Brain (g/100g BW)	0.48 ± 0.03	0.47 ± 0.03	0.50 ± 0.03	0.57 ± 0.05**
Pituitary (mg/100g BW)	2.69 ± 0.20	2.60 ± 0.34	2.69 ± 0.26	2.94 ± 0.29
Adrenals (mg/100g BW)	13.4 ± 1.1	13.0 ± 1.3	14.1 ± 2.1	13.0 ± 2.0
Testes (g/100g BW)	0.80 ± 0.04	0.77 ± 0.05	0.88 ± 0.07*	0.88 ± 0.08*
Epididymides (g/100g BW)	0.24 ± 0.02	0.23 ± 0.02	0.25 ± 0.02	0.25 ± 0.02
Prostate ventral (g/100g BW)	0.09 ± 0.01	0.09 ± 0.02	0.09 ± 0.02	0.09 ± 0.01
Prostate dorsolateral (g/100g BW)	0.34 ± 0.03	0.32 ± 0.06	0.35 ± 0.05	0.36 ± 0.04
Seminal vesicle (g/100g BW)	0.23 ± 0.03	0.21 ± 0.04	0.24 ± 0.04	0.23 ± 0.09
Females				
BW (g)	281.9 ± 12.0	271.0 ± 22.0	287.3 ± 29.9	233.9 ± 31.2*
Liver (g/100g BW)	3.48 ± 0.29	3.43 ± 0.14	3.50 ± 0.38	3.39 ± 0.32**
Kidneys (g/100g BW)	0.66 ± 0.03	0.63 ± 0.03	0.63 ± 0.04	0.61 ± 0.04
Brain (g/100g BW)	0.69 ± 0.03	0.70 ± 0.04	0.67 ± 0.07	0.78 ± 0.08*
Pituitary (mg/100g BW)	4.59 ± 0.36	4.17 ± 0.39	4.35 ± 0.67	5.44 ± 0.78**
Adrenals (mg/100g BW)	23.5 ± 3.7	22.0 ± 3.1	22.2 ± 1.9	22.2 ± 3.9
Ovaries (mg/100g BW)	31.5 ± 3.0	32.9 ± 5.4	35.8 ± 6.2	33.4 ± 5.2
Uterus (g/100g BW)	0.16 ± 0.03	0.17 ± 0.04	0.16 ± 0.03	0.19 ± 0.03
PNW 20				
No. of animals examined	10	10	10	10
Males				
BW (g)	624.9 ± 61.4 ^a	589.5 ± 60.0	583.8 ± 69.4	452.2 ± 50.5**
Liver (g/100g BW)	2.98 ± 0.16	2.99 ± 0.15	3.21 ± 0.26	2.82 ± 0.27
Kidneys (g/100g BW)	0.57 ± 0.07	0.56 ± 0.05	0.56 ± 0.04	0.58 ± 0.04
Brain (g/100g BW)	0.36 ± 0.03	0.37 ± 0.03	0.37 ± 0.05	0.45 ± 0.05**
Pituitary (mg/100g BW)	1.67 ± 0.53	1.85 ± 0.42	1.76 ± 0.26	1.99 ± 0.26
Adrenals (mg/100g BW)	9.4 ± 1.2	9.2 ± 1.7	9.1 ± 1.6	9.8 ± 1.4
Testes (g/100g BW)	0.63 ± 0.09	0.62 ± 0.06	0.68 ± 0.09	0.72 ± 0.08*
Epididymides (g/100g BW)	0.23 ± 0.02	0.22 ± 0.02	0.24 ± 0.03	0.30 ± 0.08*
Prostate ventral (g/100g BW)	0.10 ± 0.03	0.09 ± 0.02	0.09 ± 0.02	0.09 ± 0.04
Prostate dorsolateral (g/100g BW)	0.38 ± 0.12	0.32 ± 0.06	0.35 ± 0.06	0.41 ± 0.04
Seminal vesicle (g/100g BW)	0.25 ± 0.08	0.21 ± 0.04	0.23 ± 0.05	0.28 ± 0.04
Females				
BW (g)	370.2 ± 25.3	357.7 ± 26.7	366.5 ± 21.2	295.3 ± 32.6**
Liver (g/100g BW)	2.96 ± 0.28	2.94 ± 0.24	3.06 ± 0.28	3.03 ± 0.20
Kidneys (g/100g BW)	0.62 ± 0.25	0.53 ± 0.03	0.54 ± 0.04	0.53 ± 0.05
Brain (g/100g BW)	0.56 ± 0.03	0.56 ± 0.06	0.55 ± 0.04	0.65 ± 0.07*
Pituitary (mg/100g BW)	4.34 ± 0.66	4.38 ± 0.60	4.23 ± 0.72	5.08 ± 1.20
Adrenals (mg/100g BW)	17.3 ± 2.4	16.5 ± 2.5	17.5 ± 2.2	18.9 ± 3.6
Ovaries (mg/100g BW)	22.4 ± 2.8	23.0 ± 3.0	22.6 ± 3.0	24.9 ± 4.9
Uterus (g/100g BW)	0.15 ± 0.03	0.14 ± 0.02	0.15 ± 0.03	0.19 ± 0.05*

^a Mean ± SD.

Abbreviations: BW, body weight.

* , **: Significantly different from the controls (* p<0.05, ** p <0.01).

Table 6

Histopathological changes in offspring exposed gestationally and lactationally to DINP.

	No. of animals examined	DINP in maternal diet (ppm)			
		0	400	4000	20,000
Males, Week 3	No. of animals examined	10	10	10	10
Testis					
Reduction of tubular size ($\pm/+/\text{++}$) ^a		1*(0/1/0) ^c	0	2(2/0/0)	10(0/0/10) ^b
Reduction of spermatocyte development ($\pm/+/\text{++}$)		3(2/0/1)	2(2/0/0)	5(1/3/1)	10(0/1/9) ^b
Tubules with only Sertoli cells (present)		0	0	1	0
Aggregated foci of Leydig cell Incidence ^d	>20 cells	0	0	0.6±1.1*	4.0±2.3**
	≤ 20 cells	3.9±2.0	8.6±6.1	9.3±4.4*	10.7±3.0**
Epididymis					
Decreased ductular cross section, epididymal duct ($\pm/+$)		0	2(1/1)	4(2/2) ^b	6(2/4) ^b
Small ductular size, epididymal duct ($\pm/+/\text{++}$)		0	2(1/1/0)	1(1/0/0)	10(0/4/6) ^b
Mammary glands					
Alveolar bud hypoplasia ($+/+\text{++}$)		0	0	0	10(4/6) ^b
Adrenals					
Cortical atrophy ($\pm/+/\text{++}$)		0	2(1/1/0)	2(0/2/0)	10(0/3/7) ^b
Pituitary					
Diffuse atrophy, anterior lobe (++)		0	0	1	10*
Liver					
Decrease of cytoplasmic glycogen granules ($\pm/+/\text{++}/\text{+++}$)	5(4/1/0/0)	8(5/2/1/0)	10(0/10/0/0)*	10(0/0/2/8) ^b	
Increase of cytoplasmic eosinophilia ($\pm/+/\text{++}$)	0	3(3/0/0)	10(0/10/0) ^b	10(0/0/10) ^b	
Kidneys					
Dilatation, collecting tubules ($\pm/+/\text{++}$)	0	0	0	6(1/2/3) ^b	
Mineralization ($+/+\text{++}$)	0	0	0	3(2/1)	
Females, Week 3	No. of animals examined	9	10	10	10
Ovary					
Size reduction of follicles/interstitial cell layer ($\pm/+/\text{++}$)	0	5(1/4/0) ^b	6(2/4/0) ^b	10(0/0/10) ^b	
Mammary glands					
Bud hypoplasia ($\pm/+/\text{++}$)	0	0	3(2/1/0)	10(1/3/6) ^b	
Adrenals					
Cortical atrophy (++)	0	1(1/0)	1(1/0)	10(2/8) ^b	
Pituitary					
Diffuse atrophy, anterior lobe (++/+++)	0	0	0	10(7/3) ^b	
Liver					
Decrease of cytoplasmic glycogen granules ($\pm/+/\text{++}/\text{+++}$)	4(3/1/0/0)	4(4/0/0/0)	9(1/4/4/0) ^b	10(0/0/4/6) ^b	
Increase of cytoplasmic eosinophilia ($\pm/+/\text{++}$)	0	0	8(2/6/0) ^b	10(0/0/10) ^b	
Kidneys					
Dilatation, collecting tubules ($\pm/+$)	0	0	1(1/0)	9(4/5) ^b	
Mineralization, medulla ($+/+$)	0	0	0	4(3/1)*	
Males, Week 11	No. of animals examined	10	10	10	10
Testis					
Focal tubular atrophy ($\pm/$)		2(2/0)	0	3(2/1)	5(5/0)
Sertoli cell vacuolation ($\pm/$)		0	0	4(2/2) ^b	5(5/0)*
Focal Leydig cell hyperplasia (+)		0	0	1	0
Epididymis					
Intraductular cellular debris (\pm)		0	0	6*	4*
Adrenals					
Cortical atrophy ($\pm/$)		0	0	1(0/1)	7(5/2) ^b
Females, Week 11	No. of animals examined	10	10	10	10
Ovary					
Increase of follicles (+)		1	3	6*	8*
Males, Week 20	No. of animals examined	10	10	10	10
Testis					
Focal tubular atrophy (\pm)		2	1	2	5
Epididymis					
Intraductular cellular debris (\pm)		1	1	2	0
Females, Week 20	No. of animals examined	10	10	10	10
Ovary					
Increase of follicles (+)		1	3	1	2

^aGrade of change; \pm , minimal; +, slight; ++, moderate; +++, severe.^bTotal No. of animals with each change.^cNo. of animals for each grade.^dExpressed as mean \pm SD.*, ** Significantly different from the controls using parametric or non-parametric statistic method (* $p < 0.05$, ** $p < 0.01$).*, ** Significantly different from the controls using Fisher's exact probability test (* $p < 0.05$, ** $p < 0.01$).*, ** Significantly different from the controls using Mann-whitney's U-test (* $p < 0.05$, ** $p < 0.01$).

Table 7

Effects on dams and offspring until prepubertal necropsy by exposure to di-ethylhexyl adipate (DEHA) during lactation.

	DEHA in diet (ppm)			
	0	480	2400	12000
No. of dams examined	10	10	10	10
Maternal parameter				
BW change (g/day)				
GD15-GD20	13.9 ± 3.06 ^a	14.6 ± 1.4	14.6 ± 2.4	12.3 ± 1.9
PND2-PND10	4.3 ± 1.5	5.6 ± 2.2	5.7 ± 1.3	4.4 ± 2.5
PND10-PND21	-1.0 ± 1.0	-0.7 ± 0.8	-0.8 ± 0.8	-0.6 ± 1.2
Food intake (g/day)				
GD15-GD20	28.1 ± 5.6	23.6 ± 3.0	23.6 ± 2.3	20.8 ± 2.7**
PND2-PND10	44.5 ± 5.5	44.2 ± 6.7	44.7 ± 6.2	38.6 ± 3.5
PND10-PND21	61.3 ± 7.6	64.2 ± 7.3	64.9 ± 8.2	56.5 ± 4.8
DEHA intake (mg/kg/day)				
GD15-GD20	0	32.9 ± 3.3	166.0 ± 8.7	751.4 ± 83.4
PND2-PND10	0	71.3 ± 9.3	350.5 ± 34.8	1677.4 ± 198.0
PND10-PND21	0	97.6 ± 10.0	481.0 ± 58.2	2333.3 ± 230.0
Duration of pregnancy (days)	21.7 ± 0.5	21.8 ± 0.4	21.5 ± 0.5	21.5 ± 0.5
Offspring parameter				
No. of live offspring	11.6 ± 4.2	12.8 ± 1.8	11.7 ± 2.9	13.2 ± 1.5
Male ratio (%)	51.6 ± 22.5	44.1 ± 12.1	51.3 ± 14.6	51.1 ± 12.1
Body weight at PND2 (g)				
Males	7.3 ± 1.4	7.1 ± 0.9	7.3 ± 1.0	6.6 ± 0.7**
Females	7.0 ± 1.0	6.7 ± 0.8	6.6 ± 1.2	6.2 ± 0.7**
AGD at PND2 (mm)				
Males	3.9 ± 0.5	4.0 ± 0.3	3.9 ± 0.5	3.9 ± 0.3
Females	2.0 ± 0.2	2.0 ± 0.2	1.9 ± 0.2**	2.0 ± 0.2
Nipples/areolae in males at PND14				
No. of identified animales (%)	4.4%	27.7%**	24.5%**	34.0%**
Relative organ weights at PND21				
No. of animales examined	10	10	10	10
Males				
BW (g)	48.3 ± 9.1	48.2 ± 4.9	46.9 ± 6.6	42.4 ± 6.1
Liver (g/100gBW)	3.58 ± 0.28	3.76 ± 0.28	3.65 ± 0.29	3.63 ± 0.25
Kidneys (g/100gBW)	1.10 ± 0.10	1.10 ± 0.06	1.12 ± 0.12	1.09 ± 0.05
Brain (g/100gBW)	3.15 ± 0.44	3.06 ± 0.24	3.16 ± 0.37	3.47 ± 0.39
Adrenals (mg/100gBW)	27.4 ± 4.0	28.8 ± 5.7	28.3 ± 3.2	27.2 ± 2.7
Testes (g/100gBW)	0.42 ± 0.03	0.40 ± 0.04	0.42 ± 0.04	0.41 ± 0.04
Epididymides (g/100gBW)	0.08 ± 0.02	0.08 ± 0.01	0.08 ± 0.02	0.08 ± 0.01
Females				
BW (g)	48.3 ± 6.4	48.0 ± 5.4	46.2 ± 5.4	40.8 ± 3.4**
Liver (g/100gBW)	3.75 ± 0.20	3.85 ± 0.35	3.70 ± 0.18	3.75 ± 0.31
Kidneys (g/100gBW)	1.13 ± 0.05	1.18 ± 0.05	1.16 ± 0.07	1.17 ± 0.08
Brain (g/100gBW)	3.08 ± 0.35	2.99 ± 0.27	3.11 ± 0.30	3.47 ± 0.31**
Adrenals (mg/100gBW)	27.6 ± 5.3	29.1 ± 5.2	32.1 ± 6.9	31.7 ± 5.6
Ovaries (mg/100gBW)	31.5 ± 7.9	36.8 ± 7.5	27.6 ± 4.3	32.5 ± 8.5
Uterus (g/100gBW)	0.07 ± 0.01	0.07 ± 0.01	0.08 ± 0.02	0.08 ± 0.01

^a Mean±SD.

Abbreviations: GD,gestational day; PND,postnatal day; PNW,Postnatal weeks; BW, Body weight; AGD,anogenit

* ,** Significantly different from the controls (* p<0.05, **p<0.01)

Table 8

Onset of puberty and estrous cyclicity in the offspring exposed to di-ethylhexyl adipate (DEHA) during the late gestation and lactation periods.

	DEHA in diet (ppm)			
	0	480	2400	12000
Onset of puberty				
Males				
Age by day	41.1 ± 2.3 ^a	41.3 ± 1.6	41.0 ± 1.6	42.4 ± 1.9 *
BW at onset (g)	193.2 ± 17.1	186.7 ± 13.9	187.6 ± 14.8	186.3 ± 20.6
Females				
Age by day	36.3 ± 2.3	36.8 ± 2.1	35.6 ± 2.3	37.3 ± 3.2
BW at onset (g)	128.7 ± 17.7	125.1 ± 12.1	121.3 ± 12.7	118.5 ± 15.1
Estrous cyclicity				
PNW 8-11 (ED)	10(2)	10(1)	10(1)	10(2)
PNW 17-20 (ED)	10(1)	10(0)	10(0)	10(0)

^aMean±SD.

Abbreviations: BW, Body weight; ED, extended distrus.

* Significantly different from the controls ($p<0.05$).

Table 9

Organ weights at PNWs 11 and 20 of offspring exposed to di-ethylhexyl adipate (DEHA) during the late gestation and lactation periods.

	DEHA in diet (ppm)			
	0	480	2400	12000
PNW 11				
Males				
No. of animals examined	10	10	10	10
BW (g)	402.0 ± 20.3 ^a	394.4 ± 31.2	403.2 ± 20.3	370.7 ± 50.2
Liver (g/100gBW)	3.29 ± 0.33	3.42 ± 0.33	3.46 ± 0.22	3.33 ± 0.34
Kidneys (g/100gBW)	0.70 ± 0.08	0.68 ± 0.05	0.71 ± 0.07	0.66 ± 0.04
Brain (g/100gBW)	0.52 ± 0.02	0.52 ± 0.04	0.51 ± 0.03	0.54 ± 0.06
Pituitary (mg/100gBW)	3.65 ± 0.56	3.53 ± 0.21	3.86 ± 0.45	3.86 ± 0.30
Adrenals (mg/100gBW)	14.6 ± 2.5	13.5 ± 1.3	12.8 ± 1.6	13.7 ± 2.1
Testes (g/100gBW)	0.81 ± 0.06	0.77 ± 0.07	0.80 ± 0.07	0.77 ± 0.07
Epididymides (g/100gBW)	0.25 ± 0.02	0.24 ± 0.02	0.24 ± 0.02	0.24 ± 0.02
Prostate, ventral (g/100gBW)	0.16 ± 0.02	0.14 ± 0.02	0.16 ± 0.04	0.16 ± 0.03
Prostate, dorso-lateral (g/100gBW)	0.15 ± 0.02	0.14 ± 0.02	0.14 ± 0.01	0.16 ± 0.02
Seminal vesicle (g/100gBW)	0.29 ± 0.05	0.26 ± 0.05	0.26 ± 0.04	0.29 ± 0.04
Females				
No. of animals examined	10	10	11	10
BW (g)	272.5 ± 31.1	251.9 ± 33.7	265.7 ± 24.1	244.8 ± 31.5
Liver (g/100gBW)	3.38 ± 0.38	3.18 ± 0.37	3.11 ± 0.29	3.43 ± 0.46
Kidneys (g/100gBW)	0.64 ± 0.04	0.63 ± 0.04	0.66 ± 0.05	0.66 ± 0.04
Brain (g/100gBW)	0.71 ± 0.06	0.75 ± 0.08	0.70 ± 0.06	0.78 ± 0.11
Pituitary (mg/100gBW)	6.22 ± 0.82	6.06 ± 0.60	5.79 ± 0.91	6.91 ± 1.18
Adrenals (mg/100gBW)	23.4 ± 5.5	35.5 ± 15.7	31.0 ± 5.0	34.3 ± 5.5
Ovaries (mg/100gBW)	30.7 ± 5.5	35.5 ± 15.7	31.0 ± 5.0	34.3 ± 5.5
Uterus (g/100gBW)	0.16 ± 0.03	0.18 ± 0.03	0.19 ± 0.07	0.19 ± 0.05
PNW 20				
Males				
No. of animals examined	10	10	10	10
BW (g)	589.5 ± 66.1	530.1 ± 54.9	559.0 ± 70.3	522.1 ± 31.7
Liver (g/100gBW)	2.92 ± 0.26	2.75 ± 0.33	2.88 ± 0.18	2.93 ± 0.23
Kidneys (g/100gBW)	0.58 ± 0.03	0.59 ± 0.04	0.59 ± 0.05	0.59 ± 0.06
Brain (g/100gBW)	0.38 ± 0.03	0.41 ± 0.04	0.40 ± 0.04	0.42 ± 0.03
Pituitary (mg/100gBW)	2.72 ± 0.33	2.96 ± 0.15	2.87 ± 0.36	3.13 ± 0.20 **
Adrenals (mg/100gBW)	9.4 ± 1.5	9.2 ± 1.2	9.0 ± 1.1	8.6 ± 1.1
Testes (g/100gBW)	0.59 ± 0.02	0.62 ± 0.08	0.64 ± 0.09	0.62 ± 0.05
Epididymides (g/100gBW)	0.23 ± 0.02	0.25 ± 0.03	0.25 ± 0.02	0.25 ± 0.02
Prostate, ventral (g/100gBW)	0.16 ± 0.04	0.15 ± 0.03	0.15 ± 0.05	0.17 ± 0.05
Prostate, dorsolateral (g/100gBW)	0.15 ± 0.02	0.15 ± 0.02	0.17 ± 0.04	0.18 ± 0.03
Seminal vesicle (g/100gBW)	0.31 ± 0.04	0.30 ± 0.05	0.32 ± 0.05	0.33 ± 0.05
Females				
No. of animals examined	10	10	10	10
BW (g)	346.7 ± 46.9	329.8 ± 50.5	321.9 ± 28.4	304.2 ± 26.4
Liver (g/100gBW)	2.87 ± 0.41	3.05 ± 0.28	2.85 ± 0.16	2.85 ± 0.17
Kidneys (g/100gBW)	0.56 ± 0.07	0.57 ± 0.05	0.60 ± 0.07	0.59 ± 0.05
Brain (g/100gBW)	0.59 ± 0.07	0.61 ± 0.08 (9)	0.63 ± 0.05	0.67 ± 0.06
Pituitary (mg/100gBW)	5.90 ± 1.10	5.88 ± 0.86	5.89 ± 0.85	6.26 ± 0.87
Adrenals (mg/100gBW)	17.4 ± 4.0	18.2 ± 1.8	18.7 ± 3.5	19.4 ± 3.1
Ovaries (mg/100gBW)	23.8 ± 2.9	25.3 ± 4.7	25.8 ± 4.2	25.5 ± 3.4
Uterus (mg/100gBW)	0.18 ± 0.05	0.21 ± 0.08	0.20 ± 0.05	0.21 ± 0.05

*Mean±SD.

Abbreviations: BW, Body weight.

** Significantly different from the controls (p<0.01).

Table 10

Histopathological changes in offspring exposed gestationally and lactationally to DEHA.

	No.of animals examined	DEHA in maternal diet (ppm)			
		0	480	2400	12,000
Males, Week 3	No.of animals examined	10	10	10	10
Testis					
Decrease of spermatocyte development ($\pm/++$) ^a		2(1/1/0) ^b	5(1/3/1)	6(3/2/1)	5(1/4/0)
Apoptotic spermatocyte ($\pm/+$)		9(9/0)	10(8/2)	10(8/2)	10(5/5) ^c
Aggregated foci of Leydig cel Incidence ^d	>20 cells	0.1 \pm 0.3	0.1 \pm 0.3	0.3 \pm 0.5	0.7 \pm 0.9
	\leq 20 cells	5.7 \pm 2.9	9.9 \pm 3.8	9.6 \pm 3.5	12.4 \pm 5.6*
Epididymis					
Decreased cross section (+/++)		0	0	1(1/0)	3(2/1)
Mammary glands					
Bud hypoplasia (+/++)		0	0	0	6(3/3) ^c
Females, Week 3	No.of animals examined	10	10	11	10
Ovary					
Size reduction of follicles/interstitial cell layer ($\pm/++$)		2(1/1/0)	1(0/0/1)	2(1/1/0)	2(0/1/1)
Mammary glands					
Bud hypoplasia		0	0	0	1
Males, Week 11	No.of animals examined	10	10	10	10
Testis					
Tubular atrophy ($\pm/++$)		2(2/0)	0	2(2/0)	2(1/1)
Females, Week 11	No.of animals examined	10	10	11	10
Ovary					
Increase of follicles ($\pm/+$)		2(2/0)	2(1/1)	1(1/0)	5(2/3)
Males, Week 20	No.of animals examined	10	10	10	10
No abnormalities detected		10	10	10	10
Females, Week 20	No.of animals examined	10	10	10	10
Ovary					
Increase of follicles (\pm)		0	1	1	0

^aGrade of change; \pm , minimal; +, slight; ++, moderate; +++, severe.^bTotal No. of animals with each change.^cNo. of animals for each grade.^dExpressed as mean \pm SD.*,** Significantly different from the controls using parametric or non-parametric statistic method (* $p < 0.05$, ** $p < 0.01$).;^c Significantly different from the controls using Mann-whitney's U-test ($p < 0.05$, " $p < 0.01$ ").